{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:34:40Z","timestamp":1791329680706,"version":"4.3.1"},"reference-count":43,"publisher":"Informa UK Limited","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Current Medical Research and Opinion"],"published-print":{"date-parts":[[2026,2,1]]},"DOI":"10.1080\/03007995.2026.2656539","type":"journal-article","created":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T04:02:46Z","timestamp":1776916966000},"page":"281-292","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Real-world treatment patterns in metastatic castration-resistant prostate cancer progressing from metastatic hormone-sensitive prostate cancer"],"prefix":"10.1080","volume":"42","author":[{"given":"Amit D.","family":"Raval","sequence":"first","affiliation":[{"name":"Bayer HealthCare Pharmaceuticals","place":["Whippany, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orsolya","family":"Lunacsek","sequence":"additional","affiliation":[{"name":"Bayer HealthCare Pharmaceuticals","place":["Whippany, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Korn","sequence":"additional","affiliation":[{"name":"Bayer HealthCare Pharmaceuticals","place":["Whippany, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niculae","family":"Constantinovici","sequence":"additional","affiliation":[{"name":"Bayer Consumer Care","place":["Basel, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Freedland","sequence":"additional","affiliation":[{"name":"Cedars-Sinai Medical Center","place":["Los Angeles, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"key":"e_1_3_7_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040720"},{"key":"e_1_3_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(10)61389-x"},{"key":"e_1_3_7_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1014618"},{"key":"e_1_3_7_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1207506"},{"key":"e_1_3_7_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1213755"},{"key":"e_1_3_7_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322"},{"key":"e_1_3_7_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911440"},{"key":"e_1_3_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.06.009"},{"key":"e_1_3_7_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02704-x"},{"key":"e_1_3_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2023.05.021"},{"key":"e_1_3_7_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1001294"},{"key":"#cr-split#-e_1_3_7_13_1.1","unstructured":"U.S. Food and Drug Administration. FDA grants accelerated approval to pembrolizumab for first tissue\/site agnostic indication. 2017"},{"key":"#cr-split#-e_1_3_7_13_1.2","unstructured":"[cited 2026 Feb 23]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-pembrolizumab-first-tissuesite-agnostic-indication."},{"key":"e_1_3_7_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000003452"},{"key":"e_1_3_7_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2119115"},{"key":"e_1_3_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00367-1"},{"key":"e_1_3_7_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00799"},{"key":"e_1_3_7_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00193"},{"key":"e_1_3_7_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903307"},{"key":"e_1_3_7_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903835"},{"key":"e_1_3_7_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1704174"},{"key":"e_1_3_7_22_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15133402"},{"key":"e_1_3_7_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-024-00906-z"},{"key":"e_1_3_7_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyad045"},{"key":"e_1_3_7_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-022-02073-w"},{"key":"e_1_3_7_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/OP-24-00690"},{"key":"e_1_3_7_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-025-00969-6"},{"key":"e_1_3_7_28_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2021.1879753"},{"key":"e_1_3_7_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.71406"},{"key":"e_1_3_7_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2025.04.1723"},{"key":"e_1_3_7_31_1","doi-asserted-by":"publisher","DOI":"10.2307\/2137284"},{"key":"e_1_3_7_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03488"},{"key":"e_1_3_7_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.6_suppl.71"},{"key":"e_1_3_7_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.02.018"},{"key":"e_1_3_7_35_1","unstructured":"Lutetium-177 vipivotide tetraxetan US prescribing information; [cited 2024 Oct 23]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/215833s000lbl.pdf."},{"key":"e_1_3_7_36_1","unstructured":"Lutetium-177 vipivotide tetraxetan EU summary of product characteristics; [cited 2024 Oct 23]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/pluvicto-epar-product-information_en.pdf. (Accessed 23 Oct 2024)."},{"key":"e_1_3_7_37_1","unstructured":"Talazoparib US prescribing information; [cited 2024 Oct 23]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/211651s012lbl.pdf."},{"key":"e_1_3_7_38_1","unstructured":"Olaparib US prescribing information; [cited 2024 Oct 23]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/208558s028lbl.pdf."},{"key":"e_1_3_7_39_1","unstructured":"Niraparib\/abiraterone acetate fixed-dose tablets US prescribing information. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/216793s000lbl.pdf. (Accessed 23 Oct 2024)."},{"key":"e_1_3_7_40_1","unstructured":"White House. Proclamation on declaring a national emergency concerning the novel Coronavirus Disease (COVID-19) outbreak. March 13 2020; [cited 2024 Nov 6]. Available from: https:\/\/trumpwhitehouse.archives.gov\/presidential-actions\/proclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\/."},{"key":"#cr-split#-e_1_3_7_41_1.1","unstructured":"NBC News. Biden signs bill ending Covid national emergency. April 11 2023 (news release)"},{"key":"#cr-split#-e_1_3_7_41_1.2","unstructured":"[cited 2024 Nov 6]. Available from: https:\/\/www.nbcnews.com\/politics\/white-house\/biden-signs-bill-ending-covid-national-emergency-rcna79057."},{"key":"e_1_3_7_42_1","doi-asserted-by":"publisher","DOI":"10.1177\/10781552211015767"}],"container-title":["Current Medical Research and Opinion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/03007995.2026.2656539","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T17:19:22Z","timestamp":1779038362000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/03007995.2026.2656539"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,1]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2,1]]}},"alternative-id":["10.1080\/03007995.2026.2656539"],"URL":"https:\/\/doi.org\/10.1080\/03007995.2026.2656539","relation":{},"ISSN":["0300-7995","1473-4877"],"issn-type":[{"value":"0300-7995","type":"print"},{"value":"1473-4877","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,1]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=icmo20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=icmo20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-09-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-09","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}